Mark Schoeberg sells 10,000 URGN shares
Mark Schoeberg reported a sale of 10,000 ordinary shares of UroGen Pharma Ltd. The sale is listed with a transaction date of 05/08/2026 and an associated value of 300,048.00.
Rhea-AI Filing Summary
Mark Schoeberg reported a sale of 10,000 ordinary shares of UroGen Pharma Ltd. The sale is listed with a transaction date of 05/08/2026 and an associated value of 300,048.00. The filing also shows 30,000 ordinary shares issued upon vesting of RSUs on 06/08/2023 (no consideration).
Positive
- None.
Negative
- None.
Insights
Routine Form 144 sale by an insider; no additional corporate action shown.
The filing lists a reported disposition of 10,000 ordinary shares by Mark Schoeberg with a transaction date of 05/08/2026 and a reported value of 300,048.00. This appears as a standard insider sale filing under resale rules.
Separately, the record shows 30,000 shares issued upon vesting of RSUs on 06/08/2023 described as "no consideration." Timing and broader portfolio context are not provided in the excerpt.
Key Figures
Key Terms
Form 144 regulatory
RSUs financial
No consideration financial
FAQ
What does UroGen (URGN) Form 144 report for Mark Schoeberg?
AI-generated analysis. How Rhea-AI works. Not financial advice.